Valuation: Moderna, Inc.

Market Cap 27.09B 23.69B 21.86B 20.19B 38.3B 2,584B 38.95B 261B 103B 1,273B 102B 99.5B 4,375B P/E 2026 *
-7.88x
P/E 2027 * -14.3x
Enterprise Value 23.68B 20.72B 19.11B 17.65B 33.49B 2,259B 34.05B 228B 89.65B 1,113B 88.92B 86.99B 3,825B EV / Sales 2026 *
11.3x
EV / Sales 2027 * 9.82x
Free-Float
92.69%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Moderna, Inc.

1 day-10.83%
1 week-14.41%
Current month-2.51%
1 month+48.45%
3 months+33.97%
6 months+99.04%
Current year+131.50%
1 week 67.31
Extreme 67.31
85.6
1 month 49.62
Extreme 49.62
85.6
Current year 29.81
Extreme 29.81
85.6
1 year 22.28
Extreme 22.28
85.6
3 years 22.28
Extreme 22.28
170.47
5 years 22.28
Extreme 22.28
497.49
10 years 11.54
Extreme 11.54
497.49
Manager TitleAgeSince
Chief Executive Officer 54 01/03/2011
Director of Finance/CFO 49 06/09/2022
President 50 01/11/2024
Director TitleAgeSince
Chairman 63 01/02/2012
Director/Board Member 54 01/03/2011
Director/Board Member 69 11/12/2019
Date Insider Type Main position Quantity % Market Cap.
07-05Free

Executive/Senior Manager

57,022 0.0144%
07-02Fiscal year

Chief Financial Officer

3,607 0.0009%
06-15Fiscal year

Chairperson

160,008 0.0403%
Change 5-day change 1-year change 3-year change Capi.($)
-10.83%-14.41%+99.15%-44.54% 27.09B
-0.51%+1.57%+18.72%-5.52% 67.61B
-5.16%-8.63%+37.37%+202.27% 51.6B
+5.28%+39.50%+39.50%+39.50% 43B
-2.10%+0.89%-49.30%-53.47% 40.94B
+0.12%-7.85%+47.16%-29.27% 29.4B
-1.53%-0.13%+65.92%+88.58% 23.32B
+3.88%+2.16%+11.78%+201.51% 19.89B
-1.59%-1.63%+61.04%+130.75% 16.91B
-4.75%+11.27%+85.63%+394.76% 16.84B
Average -1.72%-1.59%+41.70%+92.46% 33.66B
Weighted average by Cap. -1.53%-2.13%+33.25%+66.66%

Financials

2026 *2027 *
Net sales 2.09B 1.83B 1.69B 1.56B 2.96B 200B 3.01B 20.18B 7.93B 98.36B 7.86B 7.69B 338B 2.55B 2.23B 2.06B 1.9B 3.61B 243B 3.67B 24.58B 9.65B 120B 9.57B 9.37B 412B
Net income -3.41B -2.98B -2.75B -2.54B -4.82B -325B -4.9B -32.88B -12.91B -160B -12.81B -12.53B -551B -1.85B -1.62B -1.49B -1.38B -2.62B -176B -2.66B -17.84B -7B -86.93B -6.95B -6.8B -299B
Net Debt -3.41B -2.98B -2.75B -2.54B -4.82B -325B -4.9B -32.83B -12.89B -160B -12.79B -12.51B -550B -2.05B -1.8B -1.66B -1.53B -2.9B -196B -2.95B -19.79B -7.77B -96.46B -7.71B -7.54B -332B
Logo Moderna, Inc.
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows: - revenue from product sales (96.1%); - revenue from collaboration agreements (1.5%); - revenue from royalties and licensing (1.3%); - revenue from grants (1.1%). At the end of 2024, the group's portfolio comprises 37 products in clinical development, of which 10 in phase I, 18 in phase II and 9 in phase III, 3 products in preclinical development, and 4 products in commercial phase. Net sales are distributed geographically as follows: the United States (55.1%), Europe (18.5%) and other (26.4%).
Employees
4,700
Date Price Change Volume
10/07/26 $68.27 -10.83% 9,176,930
09/07/26 $76.56 +3.74% 4,415,034
08/07/26 $73.80 -7.48% 6,581,662
07/07/26 $79.77 -2.48% 8,688,340
06/07/26 $81.80 +2.56% 17,296,875
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
23
Last Close Price
68.27USD
Average target price
47.89USD
Spread / Average Target
-29.85%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MRNA Stock